ECSP066791A - Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c - Google Patents

Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c

Info

Publication number
ECSP066791A
ECSP066791A EC2006006791A ECSP066791A ECSP066791A EC SP066791 A ECSP066791 A EC SP066791A EC 2006006791 A EC2006006791 A EC 2006006791A EC SP066791 A ECSP066791 A EC SP066791A EC SP066791 A ECSP066791 A EC SP066791A
Authority
EC
Ecuador
Prior art keywords
hepatitis
virus
inhibitors
sugar compounds
compounds
Prior art date
Application number
EC2006006791A
Other languages
English (en)
Inventor
Anil K Saksena
Raymond G Lovey
Frank Bennett
Stephane L Bogen
Yi Tsung Liu
F George Njoroge
Ashok Arasappan
Kevin X Chen
Srikanth Venkatraman
Siska Hendrata
Yuhua Huang
Latha G Nair
Viyyoor Moopil Girijavallabhan
Francisco Velazquez
Mousumi Sannigrahi
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of ECSP066791A publication Critical patent/ECSP066791A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención revela nuevos compuestos que tienen actividad inhibidora de la proteasa del VHC como así también métodos para preparar tales compuestos. En otra realización, la invención revela composiciones farmacéuticas que comprenden tales compuestos como así también métodos para usarlos para tratar trastornos asociados con la proteasa del VHC.
EC2006006791A 2004-02-27 2006-08-25 Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c ECSP066791A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54867004P 2004-02-27 2004-02-27

Publications (1)

Publication Number Publication Date
ECSP066791A true ECSP066791A (es) 2006-11-16

Family

ID=34961556

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006791A ECSP066791A (es) 2004-02-27 2006-08-25 Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c

Country Status (30)

Country Link
US (1) US8067379B2 (es)
EP (1) EP1730110B9 (es)
JP (1) JP4714732B2 (es)
KR (2) KR101316137B1 (es)
CN (2) CN101076516A (es)
AR (1) AR048241A1 (es)
AT (1) ATE470660T1 (es)
AU (1) AU2005222060A1 (es)
BR (1) BRPI0508085A (es)
CA (1) CA2557495C (es)
CY (1) CY1111212T1 (es)
DE (1) DE602005021760D1 (es)
DK (1) DK1730110T3 (es)
EC (1) ECSP066791A (es)
ES (1) ES2346233T3 (es)
HR (1) HRP20100416T1 (es)
IL (1) IL177544A (es)
MY (1) MY145081A (es)
NO (1) NO20064358L (es)
NZ (1) NZ549223A (es)
PE (1) PE20051150A1 (es)
PL (1) PL1730110T3 (es)
PT (1) PT1730110E (es)
RS (1) RS51394B (es)
RU (1) RU2428428C9 (es)
SG (1) SG186041A1 (es)
SI (1) SI1730110T1 (es)
TW (2) TWI314927B (es)
WO (1) WO2005087731A1 (es)
ZA (1) ZA200607096B (es)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
US7816326B2 (en) 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
BRPI0508085A (pt) * 2004-02-27 2007-07-17 Schering Corp compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c
GB0426661D0 (en) * 2004-12-06 2005-01-05 Isis Innovation Pyrrolidine compounds
US20060276406A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
US20060275366A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation
WO2006130687A2 (en) * 2005-06-02 2006-12-07 Schering Corporation Liver/plasma concentration ratio for dosing hepatitis c virus protease inhibitor
ES2572980T3 (es) * 2005-06-02 2016-06-03 Merck Sharp & Dohme Corp. Combinación de inhibidores de la proteasa del VHC con un tensioactivo
AU2006252623A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Controlled-release formulation useful for treating disorders associated with hepatitis C virus
US20060281689A1 (en) * 2005-06-02 2006-12-14 Schering Corporation Method for modulating activity of HCV protease through use of a novel HCV protease inhibitor to reduce duration of treatment period
US20070237818A1 (en) * 2005-06-02 2007-10-11 Malcolm Bruce A Controlled-release formulation of HCV protease inhibitor and methods using the same
US20060276404A1 (en) * 2005-06-02 2006-12-07 Anima Ghosal Medicaments and methods combining a HCV protease inhibitor and an AKR competitor
US20060276407A1 (en) * 2005-06-02 2006-12-07 Schering Corporation Methods of treating hepatitis C virus
EP1891089B1 (en) 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
AR055395A1 (es) 2005-08-26 2007-08-22 Vertex Pharma Compuestos inhibidores de la actividad de la serina proteasa ns3-ns4a del virus de la hepatitis c
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
CA2644389A1 (en) * 2006-03-03 2007-09-20 Schering Corporation Pharmaceutical combinations of hcv-protease and -ires inhibitors
EP1993993A1 (en) 2006-03-16 2008-11-26 Vertex Pharmaceuticals Incorporated Processes and intermediates for preparing steric compounds
WO2007111866A2 (en) * 2006-03-23 2007-10-04 Schering Corporation Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto
UA100666C2 (uk) 2006-04-11 2013-01-25 Новартіс Аг Інгібітори нсv/віл та їх застосування
DE102006059317A1 (de) 2006-07-04 2008-01-10 Evonik Degussa Gmbh Verfahren zur Herstellung von β-Amino-α-hydroxy-carbonsäureamiden
EP2054388A4 (en) 2006-08-17 2009-10-28 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
WO2008073282A2 (en) * 2006-12-07 2008-06-19 Schering Corporation Ph sensitive matrix formulation
US8546420B2 (en) 2006-12-22 2013-10-01 Merck Sharp & Dohme Corp. 4, 5-ring annulated indole derivatives for treating or preventing of HCV and related viral infections
JP5153648B2 (ja) * 2006-12-22 2013-02-27 住友精化株式会社 ３−ベンジルオキシベンゼンチオールの製造方法
WO2008136815A2 (en) 2006-12-22 2008-11-13 Schering Corporation 5, 6-ring annulated indole derivatives and use thereof
BRPI0720625A2 (pt) 2006-12-22 2014-03-25 Schering Corp Derivados de indol de 4,5-anel anulados e métodos de uso dos mesmos
WO2009018657A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
JP5258889B2 (ja) 2007-08-29 2013-08-07 メルク・シャープ・アンド・ドーム・コーポレーション ウイルス感染症の治療のための２，３−置換アザインドール誘導体
CA2697454C (en) 2007-08-29 2015-11-03 Schering Corporation 2-carboxy substituted indole derivatives and methods of use thereof
RU2010111550A (ru) 2007-08-29 2011-10-10 Шеринг Корпорейшн (US) 2,3-замещенные индольные производные для лечения вирусных инфекций
DK2061513T3 (da) 2007-09-14 2011-11-21 Schering Corp Fremgangsmåde til behandling af patienter med hepatitis C
AU2008309589B2 (en) 2007-10-10 2012-07-05 Novartis Ag Spiropyrrolidines and their use against HCV and HIV infection
MX2010005356A (es) 2007-11-16 2010-05-27 Schering Corp Derivados de indol 3-heterociclico sustituidos y metodos de uso de los mismos.
EP2222672B1 (en) 2007-11-16 2013-12-18 Merck Sharp & Dohme Corp. 3-aminosulfonyl substituted indole derivatives and methods of use thereof
CN103483251A (zh) 2007-12-19 2014-01-01 贝林格尔.英格海姆国际有限公司 病毒聚合酶抑制剂
US7964560B2 (en) * 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP5580814B2 (ja) 2008-06-13 2014-08-27 メルク・シャープ・アンド・ドーム・コーポレーション ３環式インドール誘導体およびその使用方法
WO2010017432A1 (en) * 2008-08-07 2010-02-11 Schering Corporation Pharmaceutical formulations of an hcv protease inhibitor in a solid molecular dispersion
US8188137B2 (en) 2008-08-15 2012-05-29 Avila Therapeutics, Inc. HCV protease inhibitors and uses thereof
EP2376078A2 (en) 2008-12-12 2011-10-19 Schering Corporation Deuterated compounds as hepatitis c virus (hcv) inhibitors
AU2010203656A1 (en) 2009-01-07 2011-07-21 Scynexis, Inc. Cyclosporine derivative for use in the treatment of HCV and HIV infection
US8512690B2 (en) 2009-04-10 2013-08-20 Novartis Ag Derivatised proline containing peptide compounds as protease inhibitors
CA2763140A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three linked aryl moieties to treat diseases such as hepatitis c
GEP20207101B (en) * 2009-07-29 2020-05-11 Merck Sharp & Dohme ENANTIO- AND STEREO-SPECIFIC SYNTHESES OF β-AMINO-α- HYDROXY AMIDES
EP2503881B1 (en) 2009-11-25 2015-05-13 Merck Sharp & Dohme Corp. Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
WO2011087740A1 (en) 2009-12-22 2011-07-21 Schering Corporation Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases
AU2011224698A1 (en) 2010-03-09 2012-11-01 Merck Sharp & Dohme Corp. Fused Tricyclic Silyl Compounds and methods of use thereof for the treatment of viral diseases
WO2012018534A2 (en) 2010-07-26 2012-02-09 Schering Corporation Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases
EP2621902B1 (en) 2010-09-28 2017-04-12 Panacea Biotec Ltd 3-azabicyclo[3.1.0]hexane compounds useful for the treatment of cns disorders
CA2812779A1 (en) 2010-09-29 2012-04-19 Merck Sharp & Dohme Corp. Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases
WO2012073249A1 (en) 2010-12-01 2012-06-07 Arch Pharmalabs Limited A novel process for the preparation of 3-(benzyloxy)- benzenethiol, a key intermediate for the preparation of pharmaceutical drugs.
US9156872B2 (en) 2011-04-13 2015-10-13 Merck Sharp & Dohme Corp. 2′-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EA201391519A1 (ru) 2011-04-13 2014-03-31 Мерк Шарп И Доум Корп. 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
WO2013033899A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
EP2755981A4 (en) 2011-09-14 2015-03-25 Merck Sharp & Dohme SILICULAR HETEROCYCLIC DERIVATIVES AND METHOD FOR THEIR USE FOR THE TREATMENT OF VIRUS DISEASES
EP3063140A4 (en) 2013-10-30 2017-11-08 Merck Sharp & Dohme Corp. Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof
WO2017059446A1 (en) * 2015-10-01 2017-04-06 Memorial Sloan-Kettering Cancer Center Anthranilyl-adenosinemonosulfamate analogs and uses thereof
US20180273573A1 (en) * 2015-10-01 2018-09-27 Memorial Sloan-Kettering Cancer Center Inhibitors of menaquinone biosynthesis
KR102512201B1 (ko) * 2016-06-21 2023-03-20 오리온 옵탈몰로지 엘엘씨 지방족 프롤린아미드 유도체
WO2020132603A2 (en) 2018-12-21 2020-06-25 Memorial Sloan-Kettering Cancer Center Salicyl-adenosinemonosulfamate analogs and uses thereof
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
US12577240B2 (en) 2020-07-11 2026-03-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
US12083099B2 (en) 2020-10-28 2024-09-10 Accencio LLC Methods of treating symptoms of coronavirus infection with viral protease inhibitors
EP4653420A1 (en) 2023-01-17 2025-11-26 Shenyang Haisco Pharmaceutical Co., Ltd. Method for preparing chiral amino alcohol pharmaceutical intermediates

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0527788T3 (da) * 1990-04-04 2004-09-06 Chiron Corp Hepatitis C virus protease
US5922757A (en) 1996-09-30 1999-07-13 The Regents Of The University Of California Treatment and prevention of hepatic disorders
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
WO1999007734A2 (en) 1997-08-11 1999-02-18 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
US6323180B1 (en) * 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
AR022061A1 (es) 1998-08-10 2002-09-04 Boehringer Ingelheim Ca Ltd Peptidos inhibidores de la hepatitis c, una composicion farmaceutica que los contiene, el uso de los mismos para preparar una composicion farmaceutica, el uso de un producto intermedio para la preparacion de estos peptidos y un procedimiento para la preparacion de un peptido analogo de los mismos.
US6608027B1 (en) * 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
DE60111509T2 (de) 2000-04-03 2006-05-11 Vertex Pharmaceuticals Inc., Cambridge Inhibitoren von Serin-Proteasen, insbesondere der Hepatitis-C-Virus NS23-Protease
JP4748911B2 (ja) 2000-04-05 2011-08-17 シェーリング コーポレイション Ｎ−環状ｐ２部分を含むｃ型肝炎ウイルスの大環状ｎｓ３‐セリンプロテアーゼ阻害剤
CN1432022A (zh) 2000-04-19 2003-07-23 先灵公司 含有烷基和芳基丙氨酸p2部分的丙型肝炎病毒的大环ns3－丝氨酸蛋白酶抑制剂
RU2003105221A (ru) 2000-07-21 2004-09-20 Шеринг Корпорейшн (US) Новые пептиды, как ингибиторы ns3-серинпротеазы вируса гепатита с
US7244721B2 (en) * 2000-07-21 2007-07-17 Schering Corporation Peptides as NS3-serine protease inhibitors of hepatitis C virus
CZ303213B6 (cs) * 2000-07-21 2012-05-23 Schering Corporation Peptidové inhibitory serinové proteázy NS3 a farmaceutický prostredek
US20020068702A1 (en) 2000-07-21 2002-06-06 Marguerita Lim-Wilby Novel peptides as NS3-serine protease inhibitors of hepatitis C virus
AR029851A1 (es) 2000-07-21 2003-07-16 Dendreon Corp Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
CN1301994C (zh) * 2000-12-12 2007-02-28 先灵公司 作为c型肝炎病毒ns3－丝氨酸蛋白酶抑制剂的二芳基肽
EP1441720B8 (en) * 2001-10-24 2012-03-28 Vertex Pharmaceuticals Incorporated Inhibitors of serine protease, particularly hepatitis c virus ns3-ns4a protease, incorporating a fused ring system
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
BRPI0508085A (pt) * 2004-02-27 2007-07-17 Schering Corp compostos de enxofre como inibidores da ns3 serina protease do vìrus da hepatite c
ES2572980T3 (es) 2005-06-02 2016-06-03 Merck Sharp & Dohme Corp. Combinación de inhibidores de la proteasa del VHC con un tensioactivo

Also Published As

Publication number Publication date
CA2557495C (en) 2014-04-15
HRP20100416T1 (hr) 2010-09-30
KR20130018418A (ko) 2013-02-21
HK1095819A1 (en) 2007-07-27
TW200938526A (en) 2009-09-16
MY145081A (en) 2011-12-15
US8067379B2 (en) 2011-11-29
CN103102389A (zh) 2013-05-15
CY1111212T1 (el) 2015-06-11
EP1730110B9 (en) 2011-11-02
KR101316137B1 (ko) 2013-10-10
ES2346233T3 (es) 2010-10-13
ATE470660T1 (de) 2010-06-15
IL177544A0 (en) 2006-12-10
NO20064358L (no) 2006-11-24
RU2428428C9 (ru) 2012-03-10
BRPI0508085A (pt) 2007-07-17
IL177544A (en) 2015-02-26
TWI393704B (zh) 2013-04-21
AU2009225346A1 (en) 2009-11-05
RU2428428C2 (ru) 2011-09-10
SG186041A1 (en) 2012-12-28
KR20060134083A (ko) 2006-12-27
RU2006134003A (ru) 2008-04-10
PT1730110E (pt) 2010-09-14
JP4714732B2 (ja) 2011-06-29
JP2007525514A (ja) 2007-09-06
WO2005087731A1 (en) 2005-09-22
TWI314927B (en) 2009-09-21
DE602005021760D1 (de) 2010-07-22
AU2005222060A1 (en) 2005-09-22
TW200530183A (en) 2005-09-16
DK1730110T3 (da) 2010-09-27
EP1730110B1 (en) 2010-06-09
AR048241A1 (es) 2006-04-12
EP1730110A1 (en) 2006-12-13
SI1730110T1 (sl) 2010-10-29
PL1730110T3 (pl) 2010-11-30
US20070042968A1 (en) 2007-02-22
PE20051150A1 (es) 2006-01-16
ZA200607096B (en) 2008-09-25
CA2557495A1 (en) 2005-09-22
RS51394B (sr) 2011-02-28
CN101076516A (zh) 2007-11-21
WO2005087731A8 (en) 2006-06-22
NZ549223A (en) 2010-10-29

Similar Documents

Publication Publication Date Title
ECSP066791A (es) Compuestos azufrados como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
ECSP066626A (es) Nuevos inhibidores de la ns3/ns4a serina proteasa del virus de la hepatitis c
ECSP066794A (es) Nuevos compuestos como inhibidores de serina proteasa ns3 del virus de la hepatitis c
ECSP066795A (es) Compuestos novedosos como inhibidores de ns3 serina proteasa del virus de hepatitis c
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
ECSP066792A (es) Cetoamidas novedosas con p4 cíclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c
ECSP045191A (es) "nuevos péptidos como inhibidores de la proteasa serina ns3 del virus de la hepatitis c"
MX2009010207A (es) Peptidos de hidrazido como inhibidores de proteasa ns3 de virus de hepatitis c.
AR029851A1 (es) Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c
TWI265927B (en) Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
MX2009010205A (es) Inhibidores de cetoamida p1-no epimerizables de proteasa ns3 de virus de hepatitis c.
ATE513844T1 (de) Acylsulfonamidverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus
MX2010004704A (es) Inhibidores macrociclicos de la ns3 serina proteasa del virus de la hepatitis c.
EA201490654A1 (ru) Новые ингибиторы вирусной репликации
WO2010021717A3 (en) Hcv protease inhibitors
WO2015095735A3 (en) Vaccine compositions and uses thereof
WO2013106689A8 (en) Hcv ns3 protease inhibitors
PH12015502230B1 (en) Novel viral replication inhibitors
WO2012061248A8 (en) Novel specific hcv ns3 protease inhibitors
WO2013012835A3 (en) Sirna useful in the treatment of flavivirus infection
AR074582A1 (es) Compuestos deuterados como inhibidores del virus de la hepatitis c (hcv)
EA201990314A1 (ru) Новые ингибиторы вирусной репликации
PH12019501907B1 (en) Viral replication inhibitors